Conference Coverage

Early PCI now favored in stable CAD


 

REPORTING FROM EUROPCR 2018


He reported no financial conflicts of interest regarding his study.

Simultaneously with Dr. Xaplanteris’ presentation of the final 5-year outcomes of FAME 2, the results were published online (N Engl J Med. 2018 May 22. doi: 10.1056/NEJMoa1803538). He reported having no financial conflicts of interest.

Similarly, Dr. Al-Lamee’s updated analysis of ORBITA was simultaneously published (Circulation. 2018 May 22. doi: 10.11161/CIRCULATIONAHA.118.033801). She, too, reported having no financial conflicts regarding this investigator-initiated study.

Dr. Haude expressed confidence that these studies will result in significant changes in the next iteration of the European Society of Cardiology guidelines on chronic coronary syndrome, likely to be issued in 2019 or 2020.

Pages

Recommended Reading

Endovascular interventions associated with large benefits in peripheral artery disease
MDedge Cardiology
Interventionalists skeptical about public reporting of PCI
MDedge Cardiology
CABANA: AF ablation ties drug management, with an asterisk for crossovers
MDedge Cardiology
Device-related thrombus associated with ischemic events
MDedge Cardiology
Design limitations may have compromised DVT intervention trial
MDedge Cardiology
For in-stent restenosis, everolimus-eluting stents topped drug-eluting balloons
MDedge Cardiology
Sapien M3 mitral valve replacement data reported for first 10 patients
MDedge Cardiology
TAVR safe in low-risk aortic stenosis, early data indicate
MDedge Cardiology
FDA recalls HeartMate 3 LV assist device
MDedge Cardiology
Breakthrough in noninvasive assessment of multivessel CAD
MDedge Cardiology